Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients

Pharmacotherapy

Volumn 27, Issue 4, 2007, Pages 603-607

  Molden, Espen ^a   Andersson, Kirsti Svendsen ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Clarithromycin; Drug interactions; Erythromycin; Rhabdomyolysis; Simvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLARITHROMYCIN; CREATINE KINASE; CYTOCHROME P450 3A4; ERYTHROMYCIN; GLYCOPROTEIN P; MACROLIDE; MYOGLOBIN; SIMVASTATIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISABILITY; DRUG METABOLISM; DRUG TRANSPORT; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL DISEASE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MALE; MUSCLE WEAKNESS; MYALGIA; NARANJO ADVERSE DRUG REACTION PROBABILITY SCALE; RATING SCALE; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 34047192918     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.4.603     Document Type: Article

References (31)

1. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107.
2. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
3. Merck & Co, Inc. Zocor (simvastatin) product information. Whitehouse Station, NJ; 2005.
4. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94:1140-6.
5. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82.
6. Kahri AJ, Valkonen MM, Vuoristo MK, Pentikainen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin [letter]. Ann Pharmacother 2004;38:719.
7. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001;35:26-31.
8. Trieu J, Emmett L, Perera C, Thanakrishnan K, Van Der Wall H. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy Clin Nucl Med 2004;29:803-4.
9. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother 2005;39:1760-1.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLB1 clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.
12. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998;351:1929-30.
13. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity Ann Pharmacother 2006;40:753-7.
14. Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996;34:400-5.
15. Hochman JH, Pudvah N, Qiu J, et al. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 2004;21:1686-91.
16. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33.
17. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51-6.
18. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very, susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
19. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53.
20. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997;31:859-63.
21. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213-15.
22. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med 1988;109:682-3.
23. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-8.
24. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988;260:239-41.
25. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J 1998;91:202-5.
26. Landesman KA, Stozek M, Freeman NJ. Rhabdomyolysis associated with the combined use of hydroxymethyl-glutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med 1999;63:455-7.
27. Molden E. Variability in cytochrome P450-mediated metabolism of cardiovascular drugs: clinical implications and practical attempts to avoid potential problems. Heart Drug 2004;4:55-79.
28. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 2003;37:808-11.
29. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV AIDS Patient Care STDS 2003;17:207-10.
30. Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol 2002;25:266-8.
31. Ciervo CA, Shi J. Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. Curr Med Res Opin 2005;21:1641-50.